Trial · NCT03406871
Adverse events126
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 126
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | dysphonia | Respiratory, thoracic and mediastinal disorders | Final Analysis: Regorafenib 120mg/Day | 2 | 25 | |
| other | dysphonia | Respiratory, thoracic and mediastinal disorders | Final Analysis: Regorafenib 160mg | 0 | 3 | |
| other | hyperthyroidism | Endocrine disorders | Final Analysis: Regorafenib 80mg/Day | 4 | 22 | |
| other | hyperthyroidism | Endocrine disorders | Final Analysis: Regorafenib 120mg/Day | 2 | 25 | |
| other | hyperthyroidism | Endocrine disorders | Final Analysis: Regorafenib 160mg | 0 | 3 | |
| other | weight decreased | Investigations | Final Analysis: Regorafenib 80mg/Day | 5 | 22 | |
| other | weight decreased | Investigations | Final Analysis: Regorafenib 120mg/Day | 2 | 25 | |
| other | weight decreased | Investigations | Final Analysis: Regorafenib 160mg | 1 | 3 | |
| other | pneumonia | Infections and infestations | Final Analysis: Regorafenib 80mg/Day | 2 | 22 | |
| other | pneumonia | Infections and infestations | Final Analysis: Regorafenib 120mg/Day | 1 | 25 | |
| other | pneumonia | Infections and infestations | Final Analysis: Regorafenib 160mg | 0 | 3 | |
| other | neutrophil count decreased | Investigations | Final Analysis: Regorafenib 80mg/Day | 1 | 22 | |
| other | neutrophil count decreased | Investigations | Final Analysis: Regorafenib 120mg/Day | 2 | 25 | |
| other | neutrophil count decreased | Investigations | Final Analysis: Regorafenib 160mg | 0 | 3 | |
| other | nasopharygititis | Infections and infestations | Final Analysis: Regorafenib 80mg/Day | 4 | 22 | |
| other | nasopharygititis | Infections and infestations | Final Analysis: Regorafenib 120mg/Day | 3 | 25 | |
| other | nasopharygititis | Infections and infestations | Final Analysis: Regorafenib 160mg | 0 | 3 | |
| other | rash | Skin and subcutaneous tissue disorders | Final Analysis: Regorafenib 80mg/Day | 7 | 22 | |
| other | rash | Skin and subcutaneous tissue disorders | Final Analysis: Regorafenib 120mg/Day | 4 | 25 | |
| other | rash | Skin and subcutaneous tissue disorders | Final Analysis: Regorafenib 160mg | 1 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03406871/events?page=3